Download PDF
Synthesis 1994; 1994(12): 1359-1368
DOI: 10.1055/s-1994-25694
paper
© Georg Thieme Verlag, Rüdigerstr. 14, 70469 Stuttgart, Germany. All rights reserved. This journal, including all individual contributions and illustrations published therein, is legally protected by copyright for the duration of the copyright period. Any use, exploitation or commercialization outside the narrow limits set by copyright legislation, without the publisher's consent, is illegal and liable to criminal prosecution. This applies in particular to photostat reproduction, copying, cyclostyling, mimeographing or duplication of any kind, translating, preparation of microfilms, and electronic data processing and storage.

Synthesis of Natural and Unnatural Enantiomers of Goniofufurone and Its 7-Epimers from D-Glucose. Application of Palladium(II) - Catalyzed Oxycarbonylation of Unsaturated Polyols

Tibor Gracza* , Volker Jäger
  • *Department of Organic Chemistry, Slovak Technical University, Radlinského 9, 812 37 Bratislava, Slovakia
Further Information

Publication History

Publication Date:
25 April 2002 (online)

  PDF Download  Permissions and Reprints All articles of this category

Syntheses of 3,6-anhydro-2-deoxy-7-phenylglyconolactones (+)-1 and (+)-2 with D- and L-glycero-D-ido configuration, respectively, as well as of their enantiomers (-)-1 and (-)-2, from D-glucose are presented. The key steps are, (i) phenylmagnesium bromide additions to C1 or C5 of glucose-derived aldehydes 7 and 10, respectively, and (ii), palladium (II)-catalyzed oxycarbonylation of intermediate 1-phenyl-D- and -L-5-hexenitols 8/9 or 14/15. The syntheses proceed in 7 steps with 6% and 18% over-all yield for (+)-1/ (+)-2, and in 6 steps/ 11% and 16% for (-)-1/ (-)-2 ( from monoacetone glucose). The absolute configurations of goniofufurone (+)-1 and its 7-epimer (+)-2 thus established are in accord with those of all suggested biogenetic precursors and allowed, e.g., to propose the absolute configuration of (+)-goniopypyrone, a related cytotoxic, bicyclic styryllactone, and structures of potential biosynthetic intermediates not identified so far.